Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws

Acta Haematologica

Volumn 124, Issue 2, 2010, Pages 79-85

  Allegra, Alessandro ^a   Alonci, Andrea ^a   Penna, Giuseppa ^a   Granata, Angela ^a   Nastro Siniscalchi, Enrico ^a   Oteri, Giacomo ^a   Loddo, Saverio ^a   Teti, Diana ^a   Cicciù, Domenico ^a   De Ponte, Francesco Saverio ^a   Musolino, Caterina ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Annexin V; Apoptosis; Bisphosphonates; Circulating endothelial cell; Multiple myeloma; Osteonecrosis

Indexed keywords

ANNEXIN; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PHOSPHATIDYLSERINE; PREDNISONE; VINCRISTINE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE NECROSIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; JAW; MALE; MULTIPLE MYELOMA; PATHOGENESIS; PRIORITY JOURNAL; ANGIOGENESIS; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; JAW DISEASE; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CELL SURVIVAL; DIPHOSPHONATES; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEONECROSIS;

EID: 77954558038     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313787     Document Type: Article

References (40)

1. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grotz KA: Incidence of bisphos-phonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009; 115: 1631-1637.
2. Woo SB, Hellstein JW, Kalmar JR: Narrative review: bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 20 06; 144 : 753-761.
3. Nastro E, Musolino C, Allegra A, Oteri G, Cicciù M, Alonci A, Quartarone E, Alati C, De Ponte FS: Bisphosphonate-associated os-teonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta He-matol 2007; 117:181-187.
4. Alonci A, Allegra A, Bellomo G, Quartarone E, Oteri G, Nastro E, Cicciù D, De Ponte FS, Musolino C: Patients with bisphosphonate- associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothe-lial growth factor receptor 1. Leuk Lymph 2007; 48:1852-1854.
5. Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zeleck L, Gligorov J, Samson J, Lesclous P, Laredo JD, Namer M: Physiopa-thology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions: a French expert panel analysis. Crit Rev Oncol Hematol 2009; 71: 12-21.
6. Lehrer S, Montazem A, Romanathan L, Pes-sin-Minsley M, Pfail J, Stock RG, Kogan R: Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009; 67: 159-161.
7. Allen MR, Burr DB: The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67:61-70.
8. Assael LA: Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Max-illofac Surg 2009; 67: 35-43.
9. Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ: Actino-mycosis of the jaw: histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007; 451:1009-1017.
10. Aons K, Kuijpers SCC, de Jong E, van Mer-kesteyn JPR: Treating low-and medium-potency bisphosphonate-related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. Oral Surg Oral Med Oral Pathol Radiol Endod 2009; 107:1-7.
11. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P: Bisphos-phonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62 : 6538-6544.
12. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effets of the bisphos-phonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061.
13. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, De-naro V, Tonini G: Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8:1080-1084.
14. Allegra A, Oteri G, Nastro E, Alonci A, Bel-lomo G, Del Fabro V, Quartarone E, Alati C, De Ponte FS, Cicciù D, Musolino C: Patients with bisphosphonates-associated osteone-crosis of the jaw have reduced circulating en-dothelial cells. Hematol Oncol 2007; 25:164-169.
15. Mariucci S, Rovati B, Chatzileontiadou S, Bencardino K, Manzoni M, Delfanti S, Da-nova M: A six-colour flow cytometric method for simultaneous detection of cell pheno-type and apoptosis of circulating endothelial cells. Scand J Clin Lab Invest 2009; 69:433-438.
16. Hristov M, Weber C: Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8:498-508.
17. Leal EC, Aveleira CA, Castilho AF, Serra AM, Baptista FI, Hosoya KI, Forrester JV, Ambrosio AF: High glucose and oxidative/ nitrosative stress conditions induce apopto-sis in retinal endothelial cells by a caspase-independent pathway. Exp Eye Res 2009; 88: 983-991.
18. Dimmeler S, Hermann C, Zeiher AM: Apop-tosis of endothelial cells: contribution to the pathophysiology of atherosclerosis? Eur Cy-tok ine Network 1998; 9: 687-689.
19. Vermes I, Haanen C, Steffens-Naken H, Reutelingsperger G: A novel assay for apop-tosis: flow cytometric detection of phospha-tidylserine expression on early apoptotic cells using fluorescein labeled annexin V. J Immunol Methods 1995; 18 4 : 39-51.
20. Fadok VA, Bratton DL, Henson PM: Phagocyte receptors for apoptotic cells: recognition, uptake and consequences. J Clin Invest 2001; 10 8: 957-962.
21. Barnett D, Janossy G, Lubenko A, Matutes A, Newland A, Reilly JT: Guidelines for the f low cytometric enumeration of CD34+ haematopoietic stem cells. Clin Lab Haematol 1999; 21: 301-308.
22. Markovic O, Marisavijevic D, Cemerikic V, Vidovi? A, Perunici? M, Todorovi? M, Elezovi? I, Colovi? M: Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance. Med Oncol 2008; 25:451-457.
23. Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B, Iver-sen PO: Increased bone marrow microvascu-lar density in haematological malignancies is associated w it h d ifferentia l regu lat ion of an-giogenic factors. Leukemia 2009; 23: 16 2-16 9.
24. Ria R, Todoerti K, Berardi S, Coluccia AM, De Luisi A, Mattioli M, Ronchetti D, Mora-bito F, Guarini A, Petrucci MT, Dammacco F, Ribatti D, Neri A, Vacca A: Gene expression profiling of bone marrow endothelial cel ls i n pat ient s w it h mu lt iple mye loma. C lin Cancer Res 2009; 15: 5369-5378 .
25. Kim WU, Kang SS, Yoo SA, Hong KH, Bae DG, Lee MS: Interaction of vascular endo-thelial growth factor 165 with neuropilin-1 protects rheumatoid sinoviocytes from apoptotic death by regulating BCL-2 expression and Bax translocation. J Immunol 2006; 17 7: 5727-5735.
26. Ruixing Y, Dezhai Y, Hai W, Kai H, Xiang-hong W, Yuming C: Intramyocardial injection of vascular endothelial cell growth factor gene improves cardiac performance and inhibits cardiomyocyte apoptosis. Eur J Hear t Fai l 2007; 9: 343-351.
27. Carneiro A, Falcao M, Pirraco A Milheiro-Oliveira P, Falcao-Reis, Soares R: Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 2009; 88:522-527.
28. Ge YL, Zhang X, Zhang JY, Hou L, Tian RH: The mechanism on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int Immunopharmacol 2009; 9: 389-395.
29. Reszka AA, Halasy-Nagy J, Rodan GA: Ni-trogen-bisphosphonates block retino blasto-ma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001; 59: 193-202 .
30. Reid IR, Bolland MJ, Grey AB: Is bisphos-phonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007; 41: 318-320.
31. Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T: Inf luence of bisphos-phonates on endothelial cells, fibroblast, and osteogenic cells. Clin Oral Invest 2010; 14: 35-41.
32. Landesberg R, Cozin M, Cremers S: Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofacial Surg 2008; 66: 839-847.
33. Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol 20 03; 13: 159-167.
34. Winn RK, Harlan JM: The role of endothe-lial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost 2005; 3: 1815-1824.
35. Bombeli T, Karsan A, Tait JF, Harlan JM: Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-2442.
36. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV: Differential effects of vascular endothelial growth factor recep-tor-2 inhibitor ZD6474 on circulating endo-thelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 20 05; 11 : 3514-3522 .
37. Ferretti G, Fabi A, Carlini P: Zoledronic-acid-induced circulating level modifications of angiogenic factors, metallo-proteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005; 69: 35-43.
38. Cetinkaya BO, Keles GC, Ayas B, Gurgor P: Effects of risedronate on alveolar bone loss and angiogenesis, a stereologic study in rats. J Periodontol 2008; 79: 1950-1961.
39. Dimmeler S, Haendeler J, Galle J, Zeiher AM: Oxidized low density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases: a mechanistic clue to the response to injury hypothesis. Circulation 1997; 95:1760-1763.
40. Terpos E, Sezer O, Croucher PI, García-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Bladé J, Cavo M, Delforge M, Dimopoulos MA, Facon T, Macro M, Waage A, Sonneveld P, European Myeloma Network: The use of bisphosphonate in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20: 1303-1317.